研究单位：[1]Huashan Hospital[2]The First Affiliated Hospital of Kunming Medical University Kunming,Yunnan,China[3]Department of Neurologic Surgery,Huashan Hospital,Shanghai Medical College,Fudan University Shanghai,Shanghai,China,200040[4]Changhai Hospital Shanghai,Shanghai,China[5]East Hospital Affiliated To Tongji University Shanghai,Shanghai,China[6]Shanghai Proton and Heavy Ion Hospital Shanghai,Shanghai,China[7]Beijing Tian Tan Hospital,Capital Medical University Beijing,Beijing,China[8]Tsinghua Changgung Hospital Beijing,Beijing,China[9]Xuan Wu Hospital,Capital Medical University Beijing,Beijing,China[10]The First Affiliated Hospital of Chongqing Medical University Chongqing,Chongqing,China
研究目的：
Given the increasing importance of patient's perspective in adverse events reporting, Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE™) has been proposed as new PRO measures in oncology; however, its implementation has not yet been evaluated in glioma patients, and standardized selection process of priority symptom terms has not been applied.
The study focuses on Chinese adult-type diffuse glioma patients. First, based on information queries, expert consultation research, online Delphi survey, and survey data analysis, the investigators will determine the questionnaire terms for PRO-CTCAE™ for adult-type diffuse gliomas patients. In the next stage, a prospective, multi-center, real-word study to assess the validity, reliability, and responsiveness of the customized PRO-CTCAE™ for adult-type diffuse gliomas patients in Chinese population will be launched (VERONICA).
